SCM
APGE

Sterling Capital Management’s Apogee Therapeutics APGE Stock Holding History

Sterling Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
158
-131
-45% -$11.8K ﹤0.01% 1865
2026
Q1 		$24.3K Buy
289
+37
+15% +$2.69K ﹤0.01% 1938
2025
Q4 		$19K Buy
252
+173
+219% +$10.9K ﹤0.01% 2253
2025
Q3 		$3.14K Buy
79
+2
+3% +$76 ﹤0.01% 2903
2025
Q2 		$3.34K Buy
77
+38
+97% +$1.45K ﹤0.01% 2726
2025
Q1 		$1.46K Hold
39
– – ﹤0.01% 2690
2024
Q4 		$1.77K Buy
39
+2
+5% +$102 ﹤0.01% 2812
2024
Q3 		$2.17K Buy
+37
New +$1.77K ﹤0.01% 2145

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Sterling Capital Management's APGE Position: Q2 2026 in Review

Sterling Capital Management reduced its Apogee Therapeutics (APGE) stake by 45% in Q2 2026, selling an estimated $11.8K and leaving 158 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Sterling Capital Management first reported a position in APGE in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.3K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Sterling Capital Management held 158 shares of Apogee Therapeutics worth $21K as of Q2 2026.
  • Sterling Capital Management sold 131 Apogee Therapeutics shares in Q2 2026, an estimated $11.8K.
  • Apogee Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1865 holding.
  • Sterling Capital Management first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Apogee Therapeutics position peaked at $24.3K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.